Promising results for new tuberculosis therapy

The preliminary findings of a study of moxifloxacin as a new treatment for TB, presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago last fall, indicated it is far more potent than standard therapy, which uses an older anti-TB drug, ethambutol. Substitutin...

Full description

Saved in:
Bibliographic Details
Published in:Canadian Medical Association journal (CMAJ) 2008-01, Vol.178 (1), p.19-19
Main Author: Bagchi, Sanjit
Format: Article
Language:English
Subjects:
Antibiotics
Antitubercular Agents - therapeutic use
Aza Compounds - therapeutic use
Clinical outcomes
Dosage and administration
Drug therapy
Drug Therapy, Combination
Evaluation
Fluoroquinolones
Humans
Moxifloxacin
Mycobacterium
Quinolines - therapeutic use
Tuberculosis
Tuberculosis - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The preliminary findings of a study of moxifloxacin as a new treatment for TB, presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago last fall, indicated it is far more potent than standard therapy, which uses an older anti-TB drug, ethambutol. Substituting moxifloxacin for ethambutol in DOTS (directly directly observed therapy short course, the standard therapy for TB) could also make treatment far less costly, allowing TB programs to expand their coverage. It could be "a significant measure to improve TB treatment, provided the treatment is more effective, safe and relatively cheaper," Bikram Saha, assistant professor of medicine at the Midnapore Medical College in West Bengal, told CMAJ.
ISSN:0820-3946
1488-2329
DOI:10.1503/cmaj.071681